Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concern
Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?
06:48am, Monday, 09'th Dec 2024
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
08:00am, Friday, 06'th Dec 2024
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concern
PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment
07:30am, Thursday, 05'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concern
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
01:11pm, Wednesday, 04'th Dec 2024
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concern
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
07:30am, Tuesday, 03'rd Dec 2024
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 --
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
10:57am, Friday, 29'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pacira BioSciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PCRX
08:00am, Friday, 29'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concer
ATTENTION Pacira BioSciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
07:30am, Tuesday, 26'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concer
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
01:25pm, Monday, 25'th Nov 2024
Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
07:25am, Monday, 25'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concer
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concer
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
11:10am, Thursday, 07'th Nov 2024
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
